KIVEXA

This brand name is authorized in Austria, Australia, Canada, Cyprus, Germany, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Ireland, Lithuania, Mexico, Netherlands, New Zealand, Poland, Romania, Singapore, United Kingdom, South Africa

Active ingredients

The drug KIVEXA contains a combination of these active pharmaceutical ingredients (APIs):

1 Abacavir
UNII J220T4J9Q2 - ABACAVIR SULFATE

Abacavir is a NRTI. It is a potent selective inhibitor of HIV-1 and HIV-2. Abacavir is metabolised intracellularly to the active moiety, carbovir 5'-triphosphate (TP). In vitro studies have demonstrated that its mechanism of action in relation to HIV is inhibition of the HIV reverse transcriptase enzyme, an event which results in chain termination and interruption of the viral replication cycle.

Read about Abacavir
2 Lamivudine
UNII 2T8Q726O95 - LAMIVUDINE

Lamivudine is a nucleoside analogue which has activity against human immunodeficiency virus (HIV) and hepatitis B virus (HBV). Its main mode of action is as a chain terminator of viral reverse transcription.

Read about Lamivudine

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
KIVEXA Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
J05AR02 Lamivudine and abacavir J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AR Antivirals for treatment of HIV infections, combinations
Discover more medicines within J05AR02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: AU Pharmaceutical Benefits Scheme Identifier(s): 10357D
Country: CA Health Products and Food Branch Identifier(s): 02269341
Country: DE Bundesinstitut für Arzneimittel und Medizinprodukte Identifier(s): 00462309, 00605571, 00910535, 01179691, 01718171, 01746345, 01973130, 02163893, 02163901, 04169730, 04911709, 04980030, 05495130, 06063958, 06560616, 06867674, 07745565, 10335428, 10335440, 11662649, 11722794, 12344472, 12575852, 13825400, 14227061, 14227078, 16529642
Country: EC Agencia Nacional de Regulación, Control y Vigilancia Sanitaria Identifier(s): 2931-MEE-0717
Country: EE Ravimiamet Identifier(s): 1198515, 1367344
Country: ES Centro de información online de medicamentos de la AEMPS Identifier(s): 04298002
Country: FI Lääkealan turvallisuus- ja kehittämiskeskus Identifier(s): 101961
Country: FR Base de données publique des médicaments Identifier(s): 69855489
Country: GB Medicines & Healthcare Products Regulatory Agency Identifier(s): 368072, 89918
Country: HK Department of Health Drug Office Identifier(s): 53855
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1029332, 1056547
Country: MX Comisión Federal para la Protección contra Riesgos Sanitarios Identifier(s): 479M2005
Country: NL Z-Index G-Standaard, PRK Identifier(s): 136050
Country: NZ Medicines and Medical Devices Safety Authority Identifier(s): 11560
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100137983
Country: RO Agenția Națională a Medicamentului și a Dispozitivelor Medicale Identifier(s): W65115001, W65115002
Country: SG Health Sciences Authority Identifier(s): 13230P
Country: ZA Health Products Regulatory Authority Identifier(s): A39/20.2.8/0030

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.